INNT
TOTAL INVALIDATION PROCESSED BY THE IB
19/02/2026
Voltar para busca
Dado oficial do USPTO
IMRELIX
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
20/02/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42, 44
Data de depósito
23/03/2017
Data de registro
24/04/2018
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
08/11/2024
Última transação
20/02/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
SE
Examinador
TIERNEY, MARGERY
Unidade examinadora
M20
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
ISR Immune System Regulation Holding AB
Immune System Regulation Holding AB
Representantes
Chas. Hude A/S
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparationspharmaceutical preparations for the treatment and prevention of viral and infectious diseases and pharmaceutical preparations for the treatment of immune dysfunction and pharmaceutical preparations for the treatment of human immunodeficiency virus
Classe 42
Scientific research within the medicalpharmaceutical and bacteriological areaSynthetic chemistry and generation of new chemical entities based on molecular structures of macrolides and of GnRH molecules to identify specific lead drug candidates for infectious diseases. Toxicology studies and preparation of investigational new drugs (INDs) according to good laboratory practice (GLP) standard operating proceduresanalysis of pharmacokinetics and metabolism of drugs and new chemical entitiespreparation of pharmaceutical formulationshigh-throughput screening of new chemical entities in the field of anti-viral therapeuticsconsultancy and information relating theretoconducting of tests regarding medical applications; packaging designdesigning and development of medical equipmentdesigning pharmaceutical and medical preparationspreparation of pharmaceutical formulationsdesign and development of granulation technology and tablet technology namelyselection of lead drug candidates in the field of anti-viral therapeutics based on specific molecular structuresdesign of pharmaceutical and medical preparations through analysis of pharmacokinetics and metbolism of drugs and new chemical entitiesmanufacturing of pharmaceutical formulations according to good manufacturing practice (GMP) standard operating proceduresconsultancy and information relating thereto
Classe 44
Information and advice relating to pharmaceutical preparationsdiseases and medical conditions and treatmentinformation and advice on-line via computer networks or the Internet and providing information relating to preventiondiagnosis and treatment of infectious diseases and information and advice relating to diagnosis and treatment of diseases and medical disorders
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
30/12/2025
XXCR
GENERIC MADRID TRANSACTION CREATED
30/12/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
21/11/2025
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
08/07/2025
C71T
CANCELLED SECTION 71
08/11/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
18/02/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
28/10/2021
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
24/01/2019
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
31/08/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/08/2018
FIMP
FINAL DISPOSITION PROCESSED
06/08/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
24/07/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
24/04/2018
PUBO
PUBLISHED FOR OPPOSITION
06/02/2018
NPUB
NOTICE OF PUBLICATION
17/01/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
28/12/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
22/12/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
22/12/2017
ALIE
ASSIGNED TO LIE
20/12/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/12/2017
RFNT
REFUSAL PROCESSED BY IB
14/07/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
29/06/2017
RFRR
REFUSAL PROCESSED BY MPU
29/06/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
20/06/2017
CNRT
NON-FINAL ACTION WRITTEN
19/06/2017
MAFR
APPLICATION FILING RECEIPT MAILED
17/06/2017
DOCK
ASSIGNED TO EXAMINER
15/06/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
13/06/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/06/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace IMRELIX ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.